- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03761927
Physiological, Behavioural and Subjective Measures of Listening Effort
July 11, 2019 updated by: Sonova AG
Effect of Noise Reduction Algorithms on Physiological, Behavioural and Subjective Measures of Listening Effort
Participants will perform two different listening tasks: (1) listening to, and repeating back, sentence lists presented in noise, and (2) listening to short radio excerpts and answering subsequent comprehension questions.
At the same time participants are required to perform a manual target-tracking task on a touch screen.
During this study, continuous, non-invasive physiological measurements (heart rate, skin conductance and hemoencephalography) will be made from participants.
Using this paradigm we will be assessing the effect of different hearing aid processing algorithms on listening effort.
The study takes the form of a three factor (listening task x algorithm x signal-to-noise ratio), within-subjects design.
Each participant performs each listening task (about 4min long each) with each algorithm (reference, noise reduction I, noise reduction II), at two signal-to-noise ratios (+4 decibel and 0 decibel) twice (test-retest).
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
17
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Stäfa, Switzerland, 8712
- Sonova AG
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 99 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Healthy outer ear (without previous surgical procedures)
- Ability to fill in a questionnaire conscientiously
- Informed Consent as documented by signature
- Minimum 1 year hearing aid experience
- Moderate-Severe (N3-N5) hearing loss or Normal Hearing
Exclusion Criteria:
- Contraindications to the MD in this study, e.g. known hypersensitivity or allergy to the investigational product
- Limited mobility and not in the position to attend weekly appointments
- Inability to produce a reliable hearing test result
- Massively limited dexterity
- Known psychological problems
- Known central hearing disorders
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Hearing Aid without NR enabled.
Hearing Aid without Noise Reduction (NR) enabled serves as reference condition.
|
Each participant will be fitted with noise reduction disabled.
Disabled means that no sound processing algorithm that removes noise from the speech signal is active.
|
Experimental: Hearing Aid with NR(1)
Hearing Aid with Noise Reduction I (NR) enabled.
|
Each participant will be fitted with the noise reduction program on the same hearing aid.
The principle of the noise reduction algorithm is to remove noise from a speech signal with the aim of improving the speech intelligibility and comfort.
|
Experimental: Hearing Aid with NR(2)
Hearing Aid with Noise Reduction II (NR) enabled.
|
Each participant will be fitted with a second noise reduction program on the same hearing aid.
The parameterization of this NR algorithm differs from that in NR(1).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Heart rate variability data
Time Frame: 6 weeks
|
Heart rate variability will be recorded from the participant both before and during the performance of the auditory tasks.
Analyses will be carried out relative to the baseline recording (made before the auditory tasks), in order to account for differences in baseline physiological activity.
Heart rate variability will be analysed in both the time [ms] and frequency [ms squared] domains.
|
6 weeks
|
Skin conductance data
Time Frame: 6 weeks
|
Skin conductance will be recorded from the participant both before and during the performance of the auditory tasks.
Analyses will be carried out relative to the baseline recording (made before the auditory tasks), in order to account for differences in baseline physiological activity.
It is planned to analyse mean levels of skin conductance [micro-Siemens].
|
6 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Hemoencephalography data
Time Frame: 6 weeks
|
Hemoencephalography will be recorded from the participant both before and during the performance of the auditory tasks.
Analyses will be carried out relative to the baseline recording (made before the auditory tasks), in order to account for differences in baseline physiological activity.
Hemoencephalography will be analysed simply as the ratio of the blue and red light [%] during auditory task performance.
|
6 weeks
|
Dual-task performance test 1
Time Frame: 6 weeks
|
Performance on the secondary tracking task will be analysed in order to observe whether there is a dual-task cost associated with performing both tasks simultaneously.
Typically the level of degradation on the secondary task is thought to reflect an increased listening effort (provided that the primary task performance remains stable).
Accordingly, success on the primary task will also be monitored and used in analyses (speech intelligibility in [%] correct).
For the Secondary task performance the reaction time [ms] will be analysed.
|
6 weeks
|
Dual-task performance test 2
Time Frame: 6 weeks
|
Performance on the secondary tracking task will be analysed in order to observe whether there is a dual-task cost associated with performing both tasks simultaneously.
Typically the level of degradation on the secondary task is thought to reflect an increased listening effort (provided that the primary task performance remains stable).
Accordingly, success on the primary task will also be monitored and used in analyses (comprehension questions [numbers] correct after listening to radio excerpts).
For the Secondary task performance the reaction time [ms] will be analysed.
|
6 weeks
|
Subjective Listening Effort rating
Time Frame: 6 weeks
|
Subjective Listening Effort will also be assessed through self-reported individual listening effort on a 14 point scale from "only noise" to "no effort" after each auditory task.
|
6 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Juliane Raether, Sonova AG
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 8, 2018
Primary Completion (Actual)
March 29, 2019
Study Completion (Actual)
April 30, 2019
Study Registration Dates
First Submitted
November 30, 2018
First Submitted That Met QC Criteria
November 30, 2018
First Posted (Actual)
December 3, 2018
Study Record Updates
Last Update Posted (Actual)
July 12, 2019
Last Update Submitted That Met QC Criteria
July 11, 2019
Last Verified
July 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Sonova2018_36
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hearing Loss
-
University of California, San FranciscoPatient-Centered Outcomes Research InstituteRecruitingHearing Loss | Hearing Loss, Sensorineural | Hearing Loss, Bilateral | Hearing Loss, Conductive | Hearing Loss, Noise-Induced | Hearing Loss, Unilateral | Hearing Loss, Mixed | Hearing Disorders in ChildrenUnited States
-
Oticon MedicalRecruitingEar Diseases | Hearing Loss, Conductive | Hearing Loss Mixed | Hearing Disability | Conductive Hearing Loss | Conductive Hearing Loss, Bilateral | Conductive Hearing Loss, UnilateralUnited Kingdom
-
MED-EL Elektromedizinische Geräte GesmbHCompletedHearing Loss | Hearing Loss, Sensorineural | Hearing Loss, Bilateral | Hearing Loss, Conductive | Hearing Loss, Unilateral | Hearing Loss, MixedAustria, Germany, United Kingdom
-
Oticon MedicalNot yet recruitingSensorineural Hearing Loss, Bilateral | Sensorineural Hearing Loss, Severe | Sensorineural Hearing Loss, Profound
-
Manchester University NHS Foundation TrustUniversity of ManchesterCompletedCochlear Hearing Loss | Sensorineural Hearing Loss, BilateralUnited Kingdom
-
Oticon MedicalCompletedConductive Hearing Loss | Conductive and Sensori-neural Hearing Loss in the Same Ear | Unilateral, Profound Sensori-neural Hearing LossUnited States
-
Frequency TherapeuticsCompletedHearing Loss, Sensorineural | Presbycusis | Noise Induced Hearing Loss | Sudden Hearing LossUnited States
-
Frequency TherapeuticsCompletedHearing Loss, Sensorineural | Noise Induced Hearing Loss | Sudden Hearing LossUnited States
-
Otologic Pharmaceutics, Inc.CompletedHearing Loss | Sensorineural Hearing Loss | Noise-Induced Hearing LossUnited States
-
Otologics LLCUnknownMixed Conductive and Sensorineural Hearing Loss, Bilateral
Clinical Trials on Hearing Aid without NR enabled
-
Sonova AGCompleted
-
Sonova AGCompletedHearing Loss | Normal HearingSwitzerland
-
Sonova AGCompleted
-
Sonova AGCompleted
-
Sonova AGCompleted
-
Northwestern UniversityNational Institute on Deafness and Other Communication Disorders (NIDCD)Completed
-
Sonova AGCompletedHearing Loss, Sensorineural | Hearing Loss, BilateralCanada
-
Bernafon AGCompletedHearing LossSwitzerland
-
Sonova AGWestern UniversityRecruiting